These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
481 related articles for article (PubMed ID: 34390244)
1. Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Holyk AA; Lindner AH; Lindner SE; Shippert BW Am J Health Syst Pharm; 2022 Jan; 79(1):e27-e33. PubMed ID: 34390244 [TBL] [Abstract][Full Text] [Related]
2. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration. Thabit AK; Hamada Y; Nicolau DP Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721 [TBL] [Abstract][Full Text] [Related]
3. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Lee TM; Villareal CL; Meyer LM Hosp Pharm; 2021 Aug; 56(4):282-286. PubMed ID: 34381262 [No Abstract] [Full Text] [Related]
4. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration. Foushee JA; Fox LM; Gormley LR; Lineberger MS Am J Health Syst Pharm; 2015 Mar; 72(6):483-6. PubMed ID: 25736944 [TBL] [Abstract][Full Text] [Related]
5. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam. Wade J; Cooper M; Ragan R Hosp Pharm; 2015 May; 50(5):376-9. PubMed ID: 26405323 [TBL] [Abstract][Full Text] [Related]
6. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Meyer K; Santarossa M; Danziger LH; Wenzler E Hosp Pharm; 2017 Mar; 52(3):221-228. PubMed ID: 28439137 [No Abstract] [Full Text] [Related]
7. Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story? Kufel WD; Miller CD; Johnson PR; Reid K; Zahra JJ; Seabury RW Hosp Pharm; 2017 Feb; 52(2):132-137. PubMed ID: 28321140 [No Abstract] [Full Text] [Related]
8. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Ruiz VH; Shen Y; Abouelhassan Y; Fouad A; Nicolau DP; Kuti JL Am J Health Syst Pharm; 2024 Jan; 81(1):e21-e29. PubMed ID: 37740370 [TBL] [Abstract][Full Text] [Related]
9. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Foushee JA; Meredith P; Fox LM; Wilder AG Am J Health Syst Pharm; 2020 Jul; 77(14):1144-1148. PubMed ID: 32537625 [TBL] [Abstract][Full Text] [Related]
10. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Trissel LA; Martinez JF Am J Hosp Pharm; 1994 Mar; 51(5):672-8. PubMed ID: 8203388 [TBL] [Abstract][Full Text] [Related]
11. Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease 2019. Kondo M; Nagano M; Yoshida M; Yoshida N; Tagui N; Yoshida M; Sugaya K; Takase H J Nippon Med Sch; 2021 Dec; 88(6):533-539. PubMed ID: 33692301 [TBL] [Abstract][Full Text] [Related]
13. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Asempa TE; Avery LM; Kidd JM; Kuti JL; Nicolau DP Am J Health Syst Pharm; 2018 Jul; 75(14):1048-1056. PubMed ID: 29895521 [TBL] [Abstract][Full Text] [Related]
14. Y-site Injection Physical Compatibility of Remdesivir with Select Intravenous Drugs Used in Palliative Care and for Treating Coronavirus Disease 2019. Kondo M; Gempei M; Watanabe K; Yoshida M; Tagui N; Fukao S; Sugaya K; Takase H J Nippon Med Sch; 2023 Nov; 90(5):381-386. PubMed ID: 37271548 [TBL] [Abstract][Full Text] [Related]
15. Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Kondo M; Yoshida N; Yoshida M; Tanaka C; Tagami T; Horikawa K; Sugaya K; Takase H Am J Health Syst Pharm; 2023 Jan; 80(1):e53-e58. PubMed ID: 36094564 [TBL] [Abstract][Full Text] [Related]
16. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions. Wilder AG; Foushee JA; Fox LM; Navalle J; Wright AM; Greer MA Int J Pharm Compd; 2020; 24(3):238-241. PubMed ID: 32401743 [TBL] [Abstract][Full Text] [Related]
17. Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration. Mody V; Shah S; Patel J; Thomas MC Int J Pharm Compd; 2016; 20(3):236-238. PubMed ID: 28333664 [TBL] [Abstract][Full Text] [Related]
18. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Trissel LA; Martinez JF Am J Hosp Pharm; 1993 Nov; 50(11):2359-63. PubMed ID: 8266963 [TBL] [Abstract][Full Text] [Related]
19. Physical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration. Tong T; Li P; Ding H; Huang Y; Liu S PLoS One; 2024; 19(3):e0299694. PubMed ID: 38517862 [TBL] [Abstract][Full Text] [Related]
20. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Hanifah S; Nugroho B; Chabib L Anaesthesiol Intensive Ther; 2020; 52(1):23-27. PubMed ID: 32024349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]